- Price
- $208.45
- Day
- +3.29%
- Mkt Cap
- $30.80B
- 52W Range
- $127.00 – $219.72
- Volume
- 1.15M
- Beta
- 0.16
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Amundi increased its stake in Biogen Inc. (NASDAQ: BIIB) by 38.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 790,827 shares of the biotechnology company's stock after buying an additional 218,398 shares during the period. Amundi owned about 0.54%
Read full article
Biogen Inc. is upgraded to 'Buy' as strategic acquisitions and pipeline progress offset multiple sclerosis portfolio erosion. Q2 revenue grew 3% Y/Y, aided by Apellis acquisition, rare disease, and Alzheimer's collaboration, with LEQEMBI gaining global traction. Felzartamab's multi-indication potential and upcoming pivotal trial readouts underpin BIIB's long-term growth prospects.
Read full article
Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead of this afternoon's Fed decision on interest rates.
Read full article
Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
Read full article
A quarter-points rate hike has been bandied about as a possibility today.
Read full article
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read full article
Biogen Inc. (BIIB) came out with quarterly earnings of $3.6 per share, beating the Zacks Consensus Estimate of $3.04 per share. This compares to earnings of $5.47 per share a year ago.
Read full article
Biogen's second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjusted earnings forecast.
Read full article
Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosis drugs stayed under pressure.
Read full article
Biogen NASDAQ: BIIB reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company's growth portfolio generated more than $1 billion in quarterly revenue, up 24% from the prior-year period.
Read full article
Biogen Inc (BIIB) released its 8-K filing on July 29, 2026, indicating notable performance in its recent quarter amid ongoing challenges in its legacy business.
Read full article
It handily beat analyst estimates on both the top and bottom lines. Investors didn't even mind a cut in adjusted net income guidance.
Read full article